Change from subcutaneous to intravenous abatacept seen as safe, effective in low disease activity RA
Please provide your email address to receive an email when new articles are posted on . Patients with rheumatoid arthritis in low disease activity or remission can safely and effectively be switched ...
BCS: Radiological Tests Little Use in Detecting Breast Mets For human epidermal growth factor receptor 2 (HER2)-positive early breast cancer, a subcutaneous formulation of trastuzumab is non-inferior ...
Ola Landgren, MD, PhD: I had 1 question I wanted to bring up. When it comes to the use of all the antibodies, daratumumab we already mentioned, daratumumab is ...
We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. Subcutaneous trastuzumab demonstrated comparable safety ...
The subcutaneous formulation of Opdivo Qvantig reduces administration time to three to five minutes, compared to 30 minutes for the IV version. This formulation offers increased convenience, ...
Panelists discuss how the shift from intravenous (IV) to subcutaneous (SubQ) drug administration is transforming oncology care delivery, highlighting its lasting impact on patient experience, health ...
Subcutaneous Opdivo showed similar efficacy and safety to intravenous Opdivo in advanced ccRCC, with a slightly higher overall response rate. The CheckMate-67T trial confirmed pharmacokinetic and ...
hands of a child with juvenile idiopathic arthritis Researchers evaluated the efficacy and safety of abatacept in pediatric patients with polyarticular-course juvenile idiopathic arthritis. ATLANTA — ...
NEW YORK (Reuters Health) - Subcutaneous daratumumab could offer an effective and more convenient alternative to the intravenous formulation for patients with relapsed or refractory multiple myeloma, ...
A phase 3 trial demonstrated shorter administration times with subcutaneous vs IV delivery of nivolumab with no significant difference in mRCC progression-free survival. Subcutaneous administration of ...
– Late-breaking Phase III results show subcutaneous injection was non-inferior to intravenous infusion based on Ocrevus levels in the blood over 12 weeks – – Ocrevus subcutaneous injection was ...
Switching from established intravenous (IV) therapy to subcutaneous infliximab was associated with high treatment persistence, stable clinical disease activity, and consistent faecal calprotectin ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results